Lexaria Bioscience (LEXX)
(Delayed Data from NSDQ)
$3.43 USD
-0.09 (-2.56%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $3.42 -0.01 (-0.29%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Lexaria Bioscience Corp falls in the month of August .
All items in Millions except EPS data.
8/31/24 | 8/31/23 | 8/31/22 | 8/31/21 | 8/31/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 1 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 7 | 8 | 6 | 3 |
Income After Depreciation & Amortization | 0 | -7 | -7 | -6 | -3 |
Non-Operating Income | NA | 0 | 0 | 2 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -7 | -7 | -4 | -4 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -7 | -7 | -4 | -4 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -7 | -7 | -4 | -4 |
Depreciation Footnote | 8/31/24 | 8/31/23 | 8/31/22 | 8/31/21 | 8/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -6 | -7 | -6 | -3 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -7 | -7 | -6 | -3 |
Earnings Per Share Data | 8/31/24 | 8/31/23 | 8/31/22 | 8/31/21 | 8/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 6.61 | 5.89 | 4.39 | 2.77 |
Diluted EPS Before Non-Recurring Items | NA | -1.01 | -1.24 | -0.95 | -1.50 |
Diluted Net EPS (GAAP) | NA | -1.01 | -1.24 | -0.95 | -1.50 |
Fiscal Year end for Lexaria Bioscience Corp falls in the month of August .
All items in Millions except EPS data.
8/31/24 | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.08 | 0.15 | 0.15 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.08 | 0.15 | 0.15 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.82 | 0.82 | 1.28 | 1.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.74 | -0.67 | -1.13 | -1.07 |
Non-Operating Income | NA | -0.04 | 0.02 | -0.05 | -0.18 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.78 | -0.65 | -1.19 | -1.25 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | -0.01 | -0.01 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.78 | -0.65 | -1.19 | -1.25 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.78 | -0.65 | -1.18 | -1.24 |
Earnings Per Share Data | 8/31/24 | 5/31/24 | 2/29/24 | 11/30/23 | 8/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 13.86 | 10.77 | 9.05 | 6.61 |
Diluted EPS Before Non-Recurring Items | NA | -0.13 | -0.06 | -0.13 | -0.12 |
Diluted Net EPS (GAAP) | NA | -0.13 | -0.06 | -0.13 | -0.12 |